Migraine: from pathophysiology to treatment
- PMID: 37029836
- PMCID: PMC10267278
- DOI: 10.1007/s00415-023-11706-1
Migraine: from pathophysiology to treatment
Abstract
Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and peripheral nervous system areas and networks. A growing increase in the understanding of migraine pathophysiology in recent years has facilitated translation of that knowledge into novel treatments, which are currently becoming available to patients in many parts of the world and are substantially changing the clinical approach to the disease. In the first part of this review, we will provide an up to date overview of migraine pathophysiology by analyzing the anatomy and function of the main regions involved in the disease, focusing on how these give rise to the plethora of symptoms characterizing the attacks and overall disease. The second part of the paper will discuss the novel therapeutic agents that have emerged for the treatment of migraine, including molecules targeting calcitonin gene-related peptide (gepants and monoclonal antibodies), serotonin 5-HT1F receptor agonists (ditans) and non-invasive neuromodulation, as well as providing a brief overview of new evidence for classic migraine treatments.
Keywords: CGRP; Migraine; Neuromodulation; Pathophysiology; Treatment.
© 2023. The Author(s).
Similar articles
-
An update on migraine: current understanding and future directions.J Neurol. 2017 Sep;264(9):2031-2039. doi: 10.1007/s00415-017-8434-y. Epub 2017 Mar 20. J Neurol. 2017. PMID: 28321564 Free PMC article. Review.
-
CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.Drugs. 2018 Jun;78(9):913-928. doi: 10.1007/s40265-018-0923-5. Drugs. 2018. PMID: 29869205 Review.
-
Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.J Intern Med. 2022 Oct;292(4):575-586. doi: 10.1111/joim.13506. Epub 2022 May 19. J Intern Med. 2022. PMID: 35532284 Free PMC article. Review.
-
Targeting CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review.Headache. 2019 Jul;59 Suppl 2:3-19. doi: 10.1111/head.13582. Headache. 2019. PMID: 31291016 Review.
-
Novel Medications for the Treatment of Migraine.Headache. 2019 Oct;59(9):1597-1608. doi: 10.1111/head.13661. Epub 2019 Sep 26. Headache. 2019. PMID: 31559638 Review.
Cited by
-
Medication-overuse headache: a narrative review.J Headache Pain. 2024 May 31;25(1):89. doi: 10.1186/s10194-024-01755-w. J Headache Pain. 2024. PMID: 38816828 Free PMC article. Review.
-
Neuroimmunological effects of omega-3 fatty acids on migraine: a review.Front Neurol. 2024 May 6;15:1366372. doi: 10.3389/fneur.2024.1366372. eCollection 2024. Front Neurol. 2024. PMID: 38770523 Free PMC article. Review.
-
Association between migraine and venous thromboembolism: a Mendelian randomization and genetic correlation study.Front Genet. 2024 May 1;15:1272599. doi: 10.3389/fgene.2024.1272599. eCollection 2024. Front Genet. 2024. PMID: 38756451 Free PMC article.
-
Female-selective mechanisms promoting migraine.J Headache Pain. 2024 Apr 24;25(1):63. doi: 10.1186/s10194-024-01771-w. J Headache Pain. 2024. PMID: 38658853 Free PMC article. Review.
-
Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS Pharmacol Transl Sci. 2024 Mar 16;7(4):951-966. doi: 10.1021/acsptsci.3c00370. eCollection 2024 Apr 12. ACS Pharmacol Transl Sci. 2024. PMID: 38633587 Review.
References
-
- Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 2013;386(9995):743–800. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials